Boundless Bio, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDBoundless Bio, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings growth of 15% provides fundamental context to the price action. However, with RSI at 83, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.65 | +55.29% | ABOVE |
| 50 SMA | $1.56 | +63.75% | ABOVE |
| 100 SMA | $1.36 | +88.29% | ABOVE |
| 150 SMA | $1.30 | +96.39% | ABOVE |
| 200 SMA | $1.29 | +97.76% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is BOLD in an uptrend right now?
BOLD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, BOLD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is BOLD overbought or oversold?
BOLD's RSI (14) is 83. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is BOLD outperforming the market?
BOLD has a Relative Strength (RS) Rating of 96 out of 99. Yes, BOLD is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is BOLD in its 52-week range?
BOLD is trading at $2.56, which is 92% of its 52-week high ($2.79) and 87% above its 52-week low ($0.96).
How volatile is BOLD?
BOLD has a Beta of -0.01 and 52-week volatility of 100%. It's less volatile than the S&P 500 - generally more stable.